{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:17:07Z","timestamp":1774862227330,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012007","name":"Rockefeller University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012007","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jid.2025.06.1588","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T06:39:03Z","timestamp":1752734343000},"page":"256-259.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential Effects of ROR\u03b3 Inhibition on Selected Pathways in Plaque Psoriasis"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-3134","authenticated-orcid":false,"given":"Denis","family":"Delic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-9272","authenticated-orcid":false,"given":"Sudha","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3248-0042","authenticated-orcid":false,"given":"Dongxia","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8330-9702","authenticated-orcid":false,"given":"Janine","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-1451","authenticated-orcid":false,"given":"Ramona","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-3027","authenticated-orcid":false,"given":"Richard","family":"Vinisko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Flack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.06.1588_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","article-title":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","volume":"109","author":"Blauvelt","year":"2023","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jid.2025.06.1588_bib2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","article-title":"The prevalent Comorbidome at the onset of psoriasis diagnosis","volume":"13","author":"Buja","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1588_bib3","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s13555-024-01262-5","article-title":"Pharmacodynamic response to Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in a global, Phase 2, randomized, double-blind, placebo-controlled psoriasis trial","volume":"14","author":"Catlett","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2025.06.1588_bib4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jid.2024.12.025","article-title":"Phase II randomized trial of BI 730357, a novel oral ROR\u03b3t inhibitor, for moderate-to-severe plaque psoriasis","volume":"145","author":"Gooderham","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1588_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acsmedchemlett.0c00575","article-title":"Discovery of a series of pyrazinone ROR\u03b3 antagonists and identification of the clinical candidate BI 730357","volume":"12","author":"Harcken","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jid.2025.06.1588_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.06.1588_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2025.06.1588_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"Immunodeficiencies. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jid.2025.06.1588_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of Brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.06.1588_bib10","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with Brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.06.1588_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2023.01.003","article-title":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","volume":"109","author":"Blauvelt","year":"2023","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jid.2025.06.1588_bib12","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jid.2024.12.025","article-title":"Phase II randomized trial of BI 730357, a novel oral ROR\u03b3t inhibitor, for moderate-to-severe plaque psoriasis","volume":"145","author":"Gooderham","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1588_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jid.2025.06.1588_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf109","article-title":"Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis [e-pub ahead of print]","author":"Kaufman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2025.06.1588_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.06.1588_bib16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2019.11.027","article-title":"Molecular and cellular responses to the TYK2\/JAK1 inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis","volume":"140","author":"Page","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.06.1588_bib17","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with Brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25022626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25022626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:34:36Z","timestamp":1774859676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25022626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022202X25022626"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1588","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Effects of ROR\u03b3 Inhibition on Selected Pathways in Plaque Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.06.1588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}